Recombinant IL-2/diphtheria toxin fusion protein (rIL-2/DTx), a drug that is FDA-approved for the treatment of cutaneous T cell lymphoma, has been reported to deplete regulatory CD4+ T cells. The gene discussed is CD4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.